HIV Drugs: Market Research Report

April 2010 | 484 pages | ID: H8EFF5CF627EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the Worldwide markets for HIV Drugs in US$ Million.

The report provides separate comprehensive analytics for US, Canada, Japan, Europe and Rest of World.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 52 companies including Abbott Laboratories, Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Koronis Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Tibotec BVBA, ViiV Healthcare, and VIRxSYS Corp.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.GLOBAL OUTLOOK

Antiretroviral Drug Market Flourishes
US Leads the Global HIV Drugs Market
NRTIs – The Largest Selling Drug Class Worldwide
HIV Prevalence on the Rise

Table 1. Global Prevalence of HIV Infection by Region (2007 & 2008) in Millions (includes corresponding Graph/Chart)

Table 2. Global Incidence of HIV Infection by Region (2007 & 2008) in Thousands (includes corresponding Graph/Chart)

Table 3. Global HIV Related Deaths by Region (2007 & 2008) in Thousands (includes corresponding Graph/Chart)

Table 4. Global Distribution of HIV Prevalence, Incidence and Mortality by Age Group (2008) (In Millions) (includes corresponding Graph/Chart)

Table 5. HIV Prevalence in Select Countries (2007) (includes corresponding Graph/Chart)

Antiretroviral Drugs – The Lone Treatment Option for HIV and AIDS
Protease Inhibitors
Select Protease Inhibitors; Dosing and Frequency

Table 6. Leading Protease Inhibitors Drugs Worldwide (2006): Value Breakdown for Kaletra, Reyataz, Norvir, Agenerase/Lexiva, Viracept and Others (includes corresponding Graph/Chart)

Overview of Select Protease Inhibitors
Kaletra (lopinavir/ritonavir)
Reyataz (Atazanavir)
Prezista (Darunavir)
Viracept (nelfinavir mesylate)
Kaletra and Reyataz to Maintain Market Dominance
Nucleoside Reverse Transcriptase Inhibitors
Approved NRTI Drugs; Dosing and Frequency
Overview of Select NRTIs
Emtriva (emtricitabine)
Stavudine (Zerit)– Marred with Safety Issues
Safety Concerns to Curb Ziagen’s Use
Non-Nucleoside Reverse Transcriptase Inhibitors
Overview of Select NNRTIs
Viramune® (nevirapine)
Intelence (Etravirine)
Integrase Inhibitors
Overview of Select Integrase Inhibitors
Isentress (Raltegravir)
Elvitegravir (Gilead Sciences)
Chemokine Receptor 5 Inhibitors
Selzentry (maraviroc)
Selzentry Makes a Slow Start
Fusion Inhibitors
Combination Therapy
Drug Resistance Issues Fuel Use of Combination Therapy
Atripla (Bristol-Myers Squibb and Gilead Sciences)
Epzicom (GlaxoSmithKline)
Quad (Gilead Sciences)
Drug Pipeline Laden With Efficacious Drugs and Novel Drug Classes
Abandoned Trials in Recent Years
Select Antiretroviral Pipeline Drugs
HIV Drug Usage Picks Up; Major Population Still Lacks Accessibility
ART Penetration Posts Significant Growth in Recent Years

Table 7. HIV-Infected Population Receiving Anti-Retroviral Treatment in Low and Middle Income Countries (2004 - 2008) (In Millions) (includes corresponding Graph/Chart)

Table 8. HIV-Infected Population Receiving and In Need of Anti-Retroviral Treatment in Low and Middle Income Countries By Region (2008) (includes corresponding Graph/Chart)

Table 9. Number of HIV Patients Receiving Antiretroviral Drugs in Select Low- and Middle-Income Countries (2008) (includes corresponding Graph/Chart)

Table 10. Number of HIV Patients Receiving Antiretroviral Drugs in Select Low- and Middle-Income Countries By Gender (2008) (includes corresponding Graph/Chart)

Table 11. Number of HIV Patients Receiving Antiretroviral Drugs in Select Low- and Middle-Income Countries By Age Group (2008) (includes corresponding Graph/Chart)

Table 12. Number of HIV Patients Receiving Antiretroviral Drugs in Select High-Income Countries (2008) (includes corresponding Graph/Chart)

Number of Children and Pregnant Women on ART Rises Dramatically

Table 13. HIV-Infected Children Receiving and In Need of Anti-Retroviral Treatment in Low and Middle Income Countries By Region (2008) (includes corresponding Graph/Chart)

Table 14. HIV-Infected Pregnant Women Receiving and In Need of Anti-Retroviral Treatment in Low and Middle Income Countries By Region (2008) (includes corresponding Graph/Chart)

Convenience and Efficacy – Key Growth Drivers
Antiretrovirals as Preventive Medicine
Cost of ARTs – A Major Barrier to Widespread Access
Manufacturers Hindering Entry of Generics
Indian Drug Manufactures Propose to Offer Low Cost Generic Versions
Need for Novel Drugs Continues
Development of Vaccines for HIV – A Challenging Task
Immune-Based Therapies Bode Promising Treatment Options for Future
Injecting Drug Users and HIV

2.COMPETITIVE SCENARIO

HIV Drug Industry - Rife With Activity
Gilead Reaches the Top, While GSK Scrambles to Gain Lost Ground

Table 15. Leading Companies in Global HIV Drugs Market (2005, 2007 & 2009): Percentage Breakdown of Revenues for Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb and Others (includes corresponding Graph/Chart)

Truvada Reigns Global HIV Drug Market; Atripla Fast Catching Up

Table 16. Worldwide Sales of Select Leading HIV Drugs (2006-2008) (includes corresponding Graph/Chart)

Atripla to Ease Truvada’s Revenue Growth
Atripla’s Success Propels Gilead’s Market Share Above GSK

3.DISEASE OVERVIEW

HIV – An Overview of the Deadly Virus
Unique Genetic Variability of HIV
Origin of HIV
Types of HIV Virus
HIV Transmission
Sexual Route
Blood Products or Blood
Mother-to-Child
Human Immune System and HIV Interaction
Stages of HIV Infection
Acute Stage of HIV Infection
Latency Stage
AIDS – Acquired Immune Deficiency Syndrome
Symptoms of HIV and AIDS Infection
HIV Testing
Diagnostic Tests for HIV and AIDS Infection
HIV Treatment

4.RECENT DRUG APPROVALS

Pfizer Obtains Expanded Indication for Selzentry from FDA
Tibotec Obtains Traditional Approval for Intelence®
FDA Confers Tentative Approval for Generic Efavirenz Tablets
FDA Clears New Dosing Recommendations for Retrovir Syrup for Infants
FDA Confers Tentative Approval for Lamivudine and Tenofovir df Tablets
Abbott Obtains EC Approval for Once-daily Dosage of Kaletra®
Merck Obtains Expanded indication for Isentress®, for use in Treatment-Naive HIV Patients
Tibotec Obtains FDA Clearance for Using Prezista in Pediatric Patients
Tibotec Obtains EU Approval for Once-daily Dosing of Prezista
Pfizer Receives FDA Clearance for Marketing Selzentry™
BMS Obtains FDA Approval for REYATAZ®/r Combination Therapy
EU Clears Tibotec’s Intelence™ in HIV Combination Therapy
Boehringer Obtains FDA Approval for Aptivus® OS
Abbott Obtains EC Approval for Lower-Strength Kaletra for Pediatric Use

5.RECENT INDUSTRY ACTIVITY

Gilead Completes Phase II Trial on Single-Dose HIV Drug, Quad
Gilead Completes Phase II Trial on Cobicistat Boosting Agent, Cobicista
Merck to Refrain from Filing NDA for Vicriviroc in Treatment-Experienced HIV-Patients
Merck’s Isentress® Receives U.S. DHHS Recommendation for Use in Treatment-Naive Patients
GSK and Pfizer Launch ViiV Healthcare
GSK and Idenix to Co-Develop New HIV Drug
Avexa Enters into Agreement with Tibotec
Gilead Enters into Agreement with Piramal Lifesciences
Avexa to Merge with Progen
Myriad Acquires Bevirimat
Vironova Signs Agreement with UMBC
Ceragenix Signs License Agreement with FPBT
Medivir to Transfer Alovudine License and IP to Beijing Mefuvir
Gilead Sciences and Merck Ink Distributing Agreement for Atripla
Boehringer Commences New Clinical Trial for Viramune® XR
EC Reinstates Marketing Authorization for Viracept
Virax Bags Additional Patent for HIV Vaccine, VIR201

6.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (US)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Gilead Sciences, Inc. (US)
Koronis Pharmaceuticals, Inc. (US)
Merck & Co., Inc. (US)
Pfizer, Inc. (US)
Tibotec BVBA (Belgium)
ViiV Healthcare (UK)
VIRxSYS Corp. (US)

7.GLOBAL MARKET PERSPECTIVE

Table 17. World Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 18. World 10-Year Perspective for HIV Drugs by Geographic Region – Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe and Rest of World Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart)

Table 19. World Recent Past, Current & Future Analysis for HIV Drugs by Product Segment – NRTIs, NNRTIs, PIs and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 20. World 10-Year Perspective for HIV Drugs by Product Segment– Percentage Breakdown of Dollar Revenues for NTRIs, NNTRIs, PIs and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.UNITED STATES

A. MARKET ANALYSIS

HIV Drugs Market Continues to Prosper
NRTIs Maintain the Lead
Select FDA–Approved Antiretroviral Drugs and Approval Date
Patent Expiries of Select Antiretroviral Drugs in the US (2010 and Beyond)
Atripla Tops US HIV Drug Chart

Table 21. Leading HIV/AIDS Drugs in the US Market (2008) in US$ Million (includes corresponding Graph/Chart)

NRTIs Losing Share In Total Prescriptions; Top Spot Remains Intact

Table 22. Percentage Breakdown of US Total Prescriptions of HIV Drugs By Class (2004-2008) (includes corresponding Graph/Chart)

Gilead Takes the Lead In NRTI Prescriptions

Table 23. Percentage Breakdown of US Total Prescriptions of NRTIs By Company (2004-2007) (includes corresponding Graph/Chart)

Table 24. Percentage Breakdown of US Total Prescriptions of NRTIs By Drug (2006-2007) (includes corresponding Graph/Chart)

Atripla Leads in Treatment-Naive HIV Market

Table 25. Leading Drugs in Treatment-Naive HIV Patient Therapeutic Market (2007) (includes corresponding Graph/Chart)

Patent Expiries to Dent Sales of GSK
Drug Assistance Programs Take the Brunt of Recession
New Drug Approvals
Strategic Corporate Developments
Select Players in the Region

B. MARKET ANALYTICS

Table 26. US Recent Past, Current & Future Analysis for HIV Drugs by Product Segment – NRTIs, NNRTIs, PIs and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 27. US 10-Year Perspective for HIV Drugs by Product Segment– Percentage Breakdown of Dollar Revenues for NTRIs, NNTRIs, PIs and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart)

2.CANADA

A. MARKET ANALYSIS

Current and Future Analysis
Approval Delays Daunting Drug Access
A Peek into the Canadian Drug Regulatory Environment
PI Drugs Continue to Witness Growth

Table 28. Canadian Sales of Protease Inhibitor Drugs (2007 & 2008) in US$ Million (includes corresponding Graph/Chart)

Select Approved Antiretroviral Drugs in Canada (1995-2006)

B. MARKET ANALYTICS

Table 29. Canadian Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3.JAPAN

A. MARKET ANALYSIS

Japan – The Fastest Growing Market for HIV Drugs Worldwide
Funding Scenario in Japan

B. MARKET ANALYTICS

Table 30. Japanese Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

4.EUROPE

A. MARKET ANALYSIS

Demand for HIV Drugs Continues to Rise
European HIV Drug Market – An Overview
Delayed Diagnosis – A Major Impediment to Increase in Survival
Limiting Factors Hitting Growth Prospects Hard
Number of New Patients Rises, While Discontinuation Rates Plummet in Leading Markets

Table 31. HIV Drugs Market in Leading EU Countries (2006): Percentage Breakdown for Italy, Spain, France, United Kingdom and Germany (includes corresponding Graph/Chart)

HAART Continues to Gain Market Share
New Drug Approvals
Strategic Corporate Developments
Select Players in the Region

B. MARKET ANALYTICS

Table 32. European Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

5.REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis
Funding Gap Threatens to Put Patients at Risk
Drugs Resistance Prompts Chinese Government to Launch Novel Drugs
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 33. Rest of World Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 52 (including Divisions/Subsidiaries - 61)
Region/CountryPlayers
The United States34
Canada
Europe
Germany
The United Kingdom
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)